NJXB(SH:600682) Xin Lang Cai Jing·2025-08-29 11:25Core Viewpoint - Nanjing Xinbai's 2025 semi-annual report indicates a slight decline in revenue but a modest increase in net profit, highlighting mixed financial performance in the first half of the year [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 3.212 billion yuan, a year-on-year decrease of 1.20% [1]. - The net profit attributable to shareholders was 166 million yuan, reflecting a year-on-year increase of 0.76% [1]. - The net profit excluding non-recurring items was 135 million yuan, showing a year-on-year decline of 23.86% [1]. - Basic earnings per share stood at 0.12 yuan [1]. Profitability Metrics - The gross profit margin for the first half of 2025 was 42.87%, down 2.71 percentage points year-on-year [2]. - The net profit margin was 6.65%, a decrease of 0.58 percentage points compared to the same period last year [2]. - In Q2 2025, the gross profit margin was 42.65%, down 4.22 percentage points year-on-year and 0.46 percentage points quarter-on-quarter [2]. - The net profit margin for Q2 2025 was 3.23%, down 0.88 percentage points year-on-year and 7.00 percentage points quarter-on-quarter [2]. Expense Management - Total operating expenses for the first half of 2025 were 951 million yuan, a decrease of 96.4 million yuan compared to the previous year [2]. - The expense ratio was 29.59%, down 2.61 percentage points year-on-year [2]. - Sales expenses decreased by 6.08%, while management expenses decreased by 15.85% [2]. - Research and development expenses increased by 3.83%, and financial expenses rose significantly by 53.88% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 40,200, a decrease of 1,797 shareholders or 4.28% from the previous quarter [2]. - The average market value per shareholder increased from 202,200 yuan to 225,300 yuan, reflecting an increase of 11.44% [2]. Company Overview - Nanjing Xinbai, established on May 14, 1991, and listed on October 18, 1993, operates in various sectors including retail, healthcare, and elderly care [3]. - The main revenue sources are health and elderly care (31.77%), pharmaceutical manufacturing (24.30%), and professional technical services (17.41%) [3]. - The company is categorized under the comprehensive industry and is associated with concepts such as stem cells, private hospitals, and the elderly care industry [3].